Insomnia Market to Observe Growth at a Paltry CAGR of 3.7% During the Study Period (2019-2032), Assesses DelveInsight
The insomnia market is projected to expand significantly from 2023 to 2032, driven by rising awareness and an increasing number of diagnosed cases. In the US, the insomnia market reached approximately USD 5.7 billion in 2022 with around 86 million diagnosed cases across the 7MM, including the US, EU-4, UK, and Japan. Key players like Vanda Pharmaceuticals and Janssen Pharmaceutical are developing innovative therapies, including HETLIOZ and Seltorexant. While the market is expected to grow at a CAGR of 3.7%, challenges such as decreasing drug revenues and subjective diagnostic methods may hinder growth.
- Insomnia market size in the US was approximately USD 5.7 billion in 2022.
- Estimated 86 million diagnosed prevalent insomnia cases in the 7MM in 2022.
- Key insomnia companies are developing novel drugs expected to enter the market soon.
- Promising therapies in the pipeline include HETLIOZ (tasimelteon) and Seltorexant (JNJ-42847922).
- Current insomnia treatments linked to side effects like decreased sleep quality and next-day drowsiness.
- Revenue decline observed for older insomnia drugs facing generic erosion.
- Insomnia diagnosis often relies on subjective complaints rather than objective measures, leading to potential misdiagnosis.
The insomnia market size is anticipated to grow during the forecast period (2023–2032) owing to the increasing awareness and increasing diagnosed prevalent population. Furthermore, the insomnia market will also be impacted by the entry of new products, which will lead to the entry of new players in the insomnia market.
Key Takeaways from the Insomnia Market Report
- As per DelveInsight analysis, the insomnia market size in the US was approximately
USD 5.7 billion in 2022. - According to the assessment done by DelveInsight, the estimated total diagnosed prevalent insomnia cases in the 7MM were approximately 86 million in 2022.
- Leading insomnia companies such as Vanda Pharmaceuticals,
Janssen Pharmaceutical , Taisho Pharmaceutical,Neurim Pharmaceuticals ,Imbrium Therapeutics ,Defined Research , and others are developing novel insomnia drugs that can be available in the Insomnia market in the coming years. - The promising insomnia therapies in the pipeline include HETLIOZ (tasimelteon), Seltorexant (JNJ-42847922), Vornorexant (TS-142), Piromelatine (Neu-P11), Sunobinop (IMB-115), Defined CBD (cannabidiol), and others.
Discover which therapies are expected to grab the major insomnia market share @ Insomnia Market Report
Insomnia Overview
Insomnia is a sleep-wake disorder that includes both nocturnal and diurnal symptoms. It is characterized by a primary complaint of dissatisfaction with sleep quality or duration. It is accompanied by difficulty falling asleep at bedtime, frequent or prolonged awakenings, or early-morning awakening with the inability to fall asleep again. There is no single known cause of insomnia. However, research suggests that in many people, it is caused by physiological arousal at inconvenient times, disrupting normal sleep patterns. The common insomnia symptoms include depression, anxiety, daytime tiredness or sleepiness, waking up too early, and others.
Insomnia is diagnosed based on the subjective complaint of difficulty initiating or maintaining sleep and reports of significant distress or daytime impairments. Actigraphy and polysomnography are currently used to measure sleep activity objectively. Although polysomnography is the gold standard for measuring sleep disorders, it is not commonly used to diagnose insomnia. Insomnia questionnaires such as the Insomnia Severity Index (ISI) and the Pittsburgh Sleep Quality Index (PSQI) are useful for insomnia diagnosis.
Insomnia Epidemiology Segmentation
DelveInsight estimates that there were approximately 86 million diagnosed prevalent cases of insomnia in the 7MM in 2022.
Among the 7MM,
The insomnia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Diagnosed Prevalent Cases
- Type-specific Cases
- Gender-specific Cases
- Age-specific Cases
Download the report to understand which factors are driving insomnia epidemiology trends @ Insomnia Epidemiological Insights
Insomnia Treatment Market
The goal of insomnia therapy is to improve the patient's ability to fall asleep, stay asleep, wake up, and function normally. Insomnia is primarily treated with behavioral and psychological therapies such as CBT-I, according to various guidelines. To treat the condition, various pharmacological therapies, such as benzodiazepines or a combination of psychologic and pharmacologic therapies, are recommended.
SOMRYST, the first and only digital therapeutic drug to treat chronic insomnia, was recently approved by the
To know more about insomnia treatment guidelines, visit @ Insomnia Management
Insomnia Pipeline Therapies and Key Companies
- HETLIOZ (tasimelteon): Vanda Pharmaceuticals
- Seltorexant (JNJ-42847922):
Janssen Pharmaceutical - Vornorexant (TS-142): Taisho Pharmaceutical
- Piromelatine (Neu-P11):
Neurim Pharmaceuticals - Sunobinop (IMB-115):
Imbrium Therapeutics - Defined CBD (cannabidiol):
Defined Research
Learn more about the FDA-approved drugs for insomnia @ Drugs for Insomnia Treatment
The dynamics of insomnia market is expected to change in the coming years due to improved diagnosis and treatment, which have resulted from increased awareness and understanding of disease pathophysiology. Moreover, significant advancements in the insomnia treatment regime have resulted in the approval of novel class therapies such as orexin antagonists and melatonin agonists, as well as CBTs, to treat insomnia and associated conditions. In addition, the advancement of biomarker discovery and research on sleep and circadian health opens up the possibility of using them as diagnostic tools and technologies for individualized treatments. Furthermore, companies have opportunities to develop drugs for chronic insomnia and insomnia caused by conditions such as MDD, AUD, and others as awareness of the condition grows. Therefore, the factors mentioned above are likely to propel the growth of the insomnia market in the coming years.
However, several factors are likely to impede the growth of the insomnia market. Insomnia is linked to decreased health-related quality of life, increased healthcare resource utilization, decreased productivity, and a significant economic burden. Most current pharmacological insomnia treatment options have been linked to side effects such as decreased sleep quality, next-day sleepiness, and an increased risk of accidents/injuries. Moreover, many approved drugs have been on the insomnia market for more than a decade and face generic erosion. The gradual decline in the revenue of drugs such as ROZEREM, SILENOR, AMBIEN, and CIRCADIN demonstrates this. Furthermore, despite changes in diagnostic criteria, the diagnosis of insomnia is still based on the patient's subjective complaints rather than laboratory-based sleep measurement, which leads to misdiagnosis.
Report Metrics | Details |
Study Period | 2019–2032 |
Coverage | 7MM [ |
Base Year | 2019 |
Insomnia Market CAGR | 3.7 % |
Insomnia Market Size in 2022 | |
Key Insomnia Companies | Vanda Pharmaceuticals, |
Key Pipeline Insomnia Therapies | HETLIOZ (tasimelteon), Seltorexant (JNJ-42847922), Vornorexant (TS-142), Piromelatine (Neu-P11), Sunobinop (IMB-115), Defined CBD (cannabidiol), and others |
Scope of the Insomnia Market Report
- Therapeutic Assessment: Insomnia current marketed and emerging therapies
- Insomnia Market Dynamics: Insomnia market drivers and barriers
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Insomnia Market Access and Reimbursement
Discover more about insomnia drugs in development @ Insomnia Clinical Trials
Table of Contents
1. | Insomnia Market Key Insights |
2. | Insomnia Market Report Introduction |
3. | Insomnia Market Overview at a Glance |
4. | Insomnia Market Executive Summary |
5. | Disease Background and Overview |
6. | Insomnia Treatment and Management |
7. | Insomnia Epidemiology and Patient Population |
8. | |
9. | Insomnia Marketed Drugs |
10. | Insomnia Emerging Drugs |
11. | Seven Major Insomnia Market Analysis |
12. | Insomnia Market Outlook |
13. | Potential of Current and Emerging Therapies |
14. | KOL Views |
15. | Insomnia Market Drivers |
16. | Insomnia Market Barriers |
17. | Unmet Needs |
18. | SWOT Analysis |
19. | Appendix |
20. | DelveInsight Capabilities |
21. | Disclaimer |
22. | About DelveInsight |
Related Reports
Insomnia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Insomnia companies, including Vanda Pharmaceuticals,
Insomnia Epidemiology Forecast
Insomnia Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted Insomnia epidemiology in the 7MM, i.e.,
Chronic Insomnia Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key chronic and Insomnia companies, including
Obstructive Sleep Apnea Market
Obstructive Sleep Apnea Market Insights, Epidemiology and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key obstructive sleep apnea companies, including
Sleep Apnea Implants Market Insights, Competitive Landscape and Market Forecast – 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key sleep apnea implants companies, including Medtronic, Siesta Medical, Inspire Medical Systems, among others.
Narcolepsy Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key narcolepsy companies, including
Sleep Apnea Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key sleep apnea companies, including Apnimed, Therapix Biosciences, Eisai,
Other Trending Reports
Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading
Connect with us on LinkedIn|Facebook|Twitter
Additionally, get in touch with our business executive to explore @ Healthcare Due Diligence Services
Contact Us
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/insomnia-market-to-observe-growth-at-a-paltry-cagr-of-3-7-during-the-study-period-20192032-assesses-delveinsight-301750515.html
SOURCE
FAQ
What is the current size of the insomnia market in the US as of 2022?
How many diagnosed insomnia cases were there in the 7MM in 2022?
What is the expected growth rate of the insomnia market from 2023 to 2032?
Who are the leading companies developing treatments for insomnia?
What are some promising new therapies for insomnia?
